Vertex Pharmaceuticals Inc

VRTXNASDAQ

Healthcare · Pharmaceutical Preparations

Market cap

$110.90B

Employees

6,400

Exchange

NASDAQ

Headquarters

BOSTON, MA

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Industry

Pharmaceutical Preparations

Sector

Healthcare

Country

US

Website

www.vrtx.com